Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders.
HANDs
MMP-9
PLGA nanoparticles
blood−brain barrier
carbon dots
darunavir
Journal
ACS chemical neuroscience
ISSN: 1948-7193
Titre abrégé: ACS Chem Neurosci
Pays: United States
ID NLM: 101525337
Informations de publication
Date de publication:
17 11 2021
17 11 2021
Historique:
pubmed:
3
11
2021
medline:
24
11
2021
entrez:
2
11
2021
Statut:
ppublish
Résumé
Human immunodeficiency virus (HIV) can independently replicate in the central nervous system (CNS) causing neurocognitive impairment even in subjects with suppressed plasma viral load. The antiretroviral drug darunavir (DRV) has been approved for therapy of HIV-infected patients, but its efficacy in the treatment of HIV-associated neurological disorders (HAND) is limited due to the low penetration through the blood-brain barrier (BBB). Therefore, innovations in DRV formulations, based on its encapsulation in optically traceable nanoparticles (NPs), may improve its transport through the BBB, providing, at the same time, optical monitoring of drug delivery within the CNS. The aim of this study was to synthesize biodegradable polymeric NPs loaded with DRV and luminescent, nontoxic carbon dots (C-Dots) and investigate their ability to permeate through an artificial BBB and to inhibit
Identifiants
pubmed: 34726377
doi: 10.1021/acschemneuro.1c00436
pmc: PMC9297288
doi:
Substances chimiques
Matrix Metalloproteinase 9
EC 3.4.24.35
Darunavir
YO603Y8113
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4286-4301Références
Expert Opin Drug Deliv. 2019 Mar;16(3):287-300
pubmed: 30779602
ACS Nano. 2013 Dec 23;7(12):11234-41
pubmed: 24246067
Ann Med. 2021 Dec;53(1):43-69
pubmed: 32841065
J Neurosci Methods. 2013 Jan 30;212(2):211-21
pubmed: 23131353
PLoS One. 2016 Apr 20;11(4):e0153451
pubmed: 27097043
Blood. 2001 Aug 15;98(4):1078-85
pubmed: 11493454
Int J Antimicrob Agents. 2009 Apr;33(4):307-20
pubmed: 19108994
AIDS. 2007 Mar 30;21(6):677-84
pubmed: 17413688
J Antimicrob Chemother. 2013 Mar;68(3):684-9
pubmed: 23143899
Mol Pharm. 2013 Jun 3;10(6):2340-9
pubmed: 23617680
J Microencapsul. 2016 Nov;33(7):669-678
pubmed: 27701988
J Biomater Appl. 2013 Mar;27(7):909-22
pubmed: 22207601
Trends Mol Med. 2007 Nov;13(11):449-59
pubmed: 18029231
Drug Deliv. 2016 Sep;23(7):2581-2586
pubmed: 25996834
J Anat. 2002 Jun;200(6):629-38
pubmed: 12162730
Colloids Surf B Biointerfaces. 2019 Mar 1;175:143-149
pubmed: 30529999
Adv Drug Deliv Rev. 2016 Aug 1;103:202-217
pubmed: 26944096
Sci Rep. 2020 Mar 2;10(1):3835
pubmed: 32123217
AIDS Res Treat. 2017;2017:2345617
pubmed: 29082041
J Neurovirol. 2000 Apr;6(2):156-63
pubmed: 10822329
Brain. 2004 Feb;127(Pt 2):398-407
pubmed: 14662518
AIDS Res Hum Retroviruses. 2009 Apr;25(4):457-61
pubmed: 19320601
Int J Nanomedicine. 2014 Apr 07;9:1757-69
pubmed: 24741312
J Neurochem. 2018 Feb;144(3):271-284
pubmed: 29210076
Mol Pharm. 2019 May 6;16(5):2069-2082
pubmed: 30916978
Open Forum Infect Dis. 2015 Dec 28;3(1):ofv210
pubmed: 26885540
Brain Behav Immun. 2015 Mar;45:1-12
pubmed: 25449672
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
Int J Nanomedicine. 2015 Mar 11;10:1985-96
pubmed: 25792832
AAPS PharmSciTech. 2018 Feb;19(2):648-660
pubmed: 28948564
Mol Pharm. 2014 Mar 3;11(3):859-71
pubmed: 24410438
PLoS One. 2015 Jun 08;10(6):e0129322
pubmed: 26053757
Ann Biomed Eng. 2010 Aug;38(8):2499-511
pubmed: 20361260
J Virol. 2002 Jun;76(12):5966-73
pubmed: 12021329
Eur J Pharm Sci. 2015 Jul 10;74:1-10
pubmed: 25845633
PLoS One. 2011;6(12):e28499
pubmed: 22174822
J Vis Exp. 2016 Aug 22;(114):
pubmed: 27583454
J Virus Erad. 2015 Apr;1(2):67-71
pubmed: 26430703
Adv Funct Mater. 2017 Oct 19;27(39):
pubmed: 30853878
Stroke. 2014 Aug;45(8):2514-26
pubmed: 24938839
Int J Pharm. 2020 Jun 15;583:119351
pubmed: 32339634
Curr Opin Lipidol. 2001 Jun;12(3):313-9
pubmed: 11353335
Tissue Barriers. 2013 Dec 1;1(5):e26882
pubmed: 24868496
J AIDS Clin Res. 2013 Nov 1;4(11):255
pubmed: 24587966
Materials (Basel). 2020 Aug 22;13(17):
pubmed: 32842684
Environ Toxicol Pharmacol. 2014 Nov;38(3):1007-15
pubmed: 25461562
Trends Immunol. 2016 Sep;37(9):608-620
pubmed: 27443914
Curr Pharm Des. 2016;22(9):1177-1193
pubmed: 26685681
Biomed Res Int. 2015;2015:484963
pubmed: 26491671
Ther Clin Risk Manag. 2009 Jun;5(3):595-615
pubmed: 19707276
Eur J Pharm Biopharm. 2019 Dec;145:65-75
pubmed: 31628997
Inflammopharmacology. 2021 Apr;29(2):561-571
pubmed: 33196947
Apoptosis. 2002 Aug;7(4):295-312
pubmed: 12101389
J Neurovirol. 2009 May;15(3):275-81
pubmed: 19444696
Trends Pharmacol Sci. 2010 Jan;31(1):22-35
pubmed: 20004485
Virus Res. 2005 Aug;111(2):194-213
pubmed: 15885841
Circ Res. 2003 May 2;92(8):827-39
pubmed: 12730128
Brain Behav Immun. 2017 Oct;65:161-172
pubmed: 28487203
J Neurovirol. 2013 Oct;19(5):452-60
pubmed: 23979706
J Control Release. 2017 May 10;253:1-10
pubmed: 28215668
Drugs. 2013 Jun;73(9):893-905
pubmed: 23733447
Adv Colloid Interface Sci. 2020 Apr;278:102123
pubmed: 32087367
Nanomedicine (Lond). 2011 Feb;6(2):377-94
pubmed: 21385139
J Med Life. 2011 Nov 14;4(4):432-9
pubmed: 22514580
Eur J Pharm Biopharm. 2010 Feb;74(2):157-63
pubmed: 19755158
Lab Chip. 2005 Jan;5(1):74-85
pubmed: 15616743
Nanoscale. 2019 Nov 21;11(43):20411-20428
pubmed: 31641702